63214-58-4

Basic information

• Product Name: 1-(PIPERIDIN-4-YLCARBONYL)PIPERIDINE
• Synonyms: PIPERIDINO(4-PIPERIDINYL)METHANONE;PIPERIDIN-4-YL-PIPERIDIN-1-YL-METHANONE;ART-CHEM-BB B025011;CBI-BB ZERO/005420;CHEMBRDG-BB 4003426;1-(PIPERIDIN-4-YLCARBONYL)PIPERIDINE;AKOS B025011;(Piperidin-1-yl)(Piperidin-4-yl)methanone
• CAS NO: 63214-58-4
• Molecular Formula: C₁₁H₂₀N₂O
• Molecular Weight: 196.29
• Mol File: 63214-58-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 350.5 °C at 760 mmHg
• Flash Point: 165.8 °C
• Appearance: /
• Density: 1.047 g/cm³
• Vapor Pressure: 4.37E-05mmHg at 25°C
• Refractive Index: 1.505
• PKA: 10.05±0.10(Predicted)
• CAS DataBase Reference: 1-(PIPERIDIN-4-YLCARBONYL)PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(PIPERIDIN-4-YLCARBONYL)PIPERIDINE(63214-58-4)
• EPA Substance Registry System: 1-(PIPERIDIN-4-YLCARBONYL)PIPERIDINE(63214-58-4)

Safety Data

• Hazard Codes: C,Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 63214-58-4(Hazardous Substances Data)

Usage

General Description

1-(piperidin-4-ylcarbonyl)piperidine is a chemical compound that belongs to the class of piperidine derivatives. It is composed of two piperidine rings, with one ring containing a piperidin-4-ylcarbonyl group. 1-(PIPERIDIN-4-YLCARBONYL)PIPERIDINE has potential applications in medicinal chemistry and pharmaceutical research, as it may exhibit biological activity due to its structural features. The presence of the piperidin-4-ylcarbonyl group suggests that 1-(piperidin-4-ylcarbonyl)piperidine could have specific interactions with biological targets, making it a potentially interesting molecule for drug discovery and development. Further research and characterization of this compound may lead to the identification of new therapeutic agents or lead compounds for various medical conditions.

InChI:InChI=1/C11H20N2O/c14-11(10-4-6-12-7-5-10)13-8-2-1-3-9-13/h10,12H,1-9H2

Upstream product

• 110-89-4 piperidine 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 4968-87-0 piperidin-1-yl(pyridin-4-yl)methanone 
• 757949-38-5 4-(piperidine-1-carbonyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 147635-70-9 4-(Piperidine-1-carbonyl)-piperidine-1-carboxylic acid benzyl ester 

Downstream Products

• 86543-11-5 4-(Piperidine-1-carbonyl)-piperidine-1-carbothioic acid (2-cyano-4,5-dimethoxy-phenyl)-amide 
• 80030-54-2 N-(2-Cyano-4,5-dimethoxy-phenyl)-4-(piperidine-1-carbonyl)-piperidine-1-carboximidothioic acid methyl ester 
• 893086-61-8 4-piperidin-1-ylmethyl-piperidine-1-carboxylic acid (4-bromo-phenyl)amide 
• 1084952-95-3 (1-(4-(6-(6-amino-5-trifluoromethylpyridin-3-yl)imidazo[1,2-b]pyridazin-3-yl)benzyl)piperidin-4-yl)piperidin-1-ylmethanone 
• 1401618-58-3 (1-(4-fluorobenzyl)-1H-indol-2-yl)(4-(piperidine-1-carbonyl)piperidin-1-yl)methanone 
• 1084953-34-3 4-(4-(piperidine-1-ylcarbonyl)piperidin-1-ylmethyl)phenylboronic acid 
• 32470-52-3 4-(piperidin-1-yl)methyl-piperidine 

Relevant articles and documents

Design, synthesis and antitubercular evaluation of benzothiazinones containing a piperidine moiety

We herein report the design and synthesis of benzothiazinones containing a piperidine moiety as new antitubercular agents based on the structure feature of IMB-ZR-1 discovered in our lab. Some of them were found to have good in vitro activity (MIC 1 μg/

MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF

Compounds with α7 nicotinic acetylcholine receptor (α7 nAChR) agonistic activity, processes for their preparation, pharmaceutical compositions containing the same and the use thereof for the treatment of neurological and psychiatric diseases.

Synthesis and antihypertensive activity of some new quinazoline derivatives

A series of substituted 2-piperidino-4-amino-6,7-dimethoxyquinazolines was synthesized and screened as potential antihypertensive agents. The hypotensive effect of all the new compounds was studied after intravenous administrations in urethane-anesthetized normotensive rats. The furoylpiperazine moiety in the prazosin molecule could be replaced by a more stable substituted piperidine group without loss of the blood pressure lowering activity. However, the nature of the substituent profoundly influenced the hypotensive potency as well as the duration of the hypotensive action. Some of the new compounds were found to be as potent as prazosin. On the basis of potency and the duration of the hypotensive action in the anesthetized rats, five of the most promising compounds were selected for further studies. Each of these agents exerted an antihypertensive effect upon oral administrations in conscious spontaneously hypertensive rats. At small doses, the new compounds appeared to be somewhat less potent than prazosin, but at the higher doses of 10-100 μmol/kg, two of them appeared to be even more efficacious antihypertensive agents than prazosin.